Anti-PD-1 shows promise against advanced paediatric Hodgkin lymphoma
- PMID: 32135110
- DOI: 10.1016/S1470-2045(20)30077-2
Anti-PD-1 shows promise against advanced paediatric Hodgkin lymphoma
Comment in
-
Anti-PD-1 shows promise against advanced paediatric Hodgkin lymphoma - Author's reply.Lancet Oncol. 2020 Mar;21(3):e127. doi: 10.1016/S1470-2045(20)30105-4. Lancet Oncol. 2020. PMID: 32135111 No abstract available.
Comment on
-
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.Lancet Oncol. 2020 Jan;21(1):121-133. doi: 10.1016/S1470-2045(19)30671-0. Epub 2019 Dec 4. Lancet Oncol. 2020. PMID: 31812554 Clinical Trial.
Similar articles
-
Anti-PD-1 shows promise against advanced paediatric Hodgkin lymphoma - Author's reply.Lancet Oncol. 2020 Mar;21(3):e127. doi: 10.1016/S1470-2045(20)30105-4. Lancet Oncol. 2020. PMID: 32135111 No abstract available.
-
Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin's Lymphoma.Radiat Res. 2018 Sep;190(3):322-329. doi: 10.1667/RR15048.1. Epub 2018 Jun 27. Radiat Res. 2018. PMID: 29949442 Free PMC article.
-
A promising start for checkpoint inhibitors in childhood malignancies.Lancet Oncol. 2020 Jan;21(1):13-14. doi: 10.1016/S1470-2045(19)30803-4. Epub 2019 Dec 4. Lancet Oncol. 2020. PMID: 31812553 No abstract available.
-
Pembrolizumab for the treatment of diffuse large B-cell lymphoma.Expert Opin Biol Ther. 2019 Nov;19(11):1119-1126. doi: 10.1080/14712598.2019.1659777. Epub 2019 Aug 28. Expert Opin Biol Ther. 2019. PMID: 31456438 Review.
-
L’arrivée de l’immunothérapie dans le lymphome de Hodgkin.Bull Cancer. 2018 Dec;105 Suppl 1:S50-S58. doi: 10.1016/S0007-4551(18)30390-4. Bull Cancer. 2018. PMID: 30595199 Review. French.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical